Effects of hyperbaric oxygen therapy on neurological function, Th17/Treg levels and TLR2/NF-κB pathway in children with viral encephalitis
10.3760/cma.j.cn311847-20200513-00198
- VernacularTitle:高压氧治疗对病毒性脑炎患儿脑神经功能、Th17/Treg细胞水平以及TLR2/NF-κB通路的影响
- Author:
Renjun LI
1
;
Xiaoling REN
;
Yalin RAN
Author Information
1. 401336 重庆，重庆市东南医院儿科
- Publication Type:Journal Article
- Keywords:
Viral encephalitis;
Hyperbaric oxygen;
Neurological function;
TLR2/NF-κB pathway;
Regulatory T cells;
Th17
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2021;28(4):469-474
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of hyperbaric oxygen therapy (HBOT) on neurological function, Th17/Treg levels, and TLR2/NF-κB pathway in children with viral encephalitis (VE).Methods:A total of 76 children with VE admitted to the Dadukou People’s Hospital between April 2017 and April 2019 were selected as the research subjects and randomly assigned to two groups ( n=38) by the random number table method. The children in the control group received conventional treatment, and those in the HBOT group additionally received HBOT. The clinical treatment effects, the results of electroencephalogram (EEG) examination, the mini-mental state examination(MMSE), the serum inflammatory factors, the central nerve specific protein (S100β), the neuron-specific enolase (NSE), the peripheral blood Th17/ regulatory T cells (Treg), and TLR2/NF-κB pathway levels were compared. There were no significant differences in those indicators between the two groups before treatment ( P>0.05). Results:The time period for the clinical symptoms to disappear in the HBOT group was significantly shorter than that in the control group ( P<0.05). The times of seizure onset in the HBOT group were significantly less than those in the control group ( P<0.05). After treatment, the proportions of moderate and severe EEG abnormalities in the HBOT group were significantly lower than those in the control group ( P<0.05), the proportion of EEG returning to normal state was significantly higher than that in the control group ( P<0.05), and the recovery time period of EEG in the HBOT group was significantly shorter than that in the control group ( P<0.05). After treatment, the MMSE score of the HBOT group was higher than that of the control group [(28.16±8.29)>(20.21±4.40), P<0.05]. The levels of IL-1, CRP, S100β, and NSE in the HBOT group were significantly lower than those in the control group ( P<0.05). After treatment, the level of Th17 in the HBOT group was significantly lower than that in the control group [(0.024±0.004)% vs. (0.028±0.01)%, P<0.05], and the level of Treg was significantly higher than that in the control group [(0.016±0.003)% vs. (0.014±0.004)%, P<0.05]. The levels of TLR2, Myd88, and NF-κB protein in the HBOT group were significantly lower than those in the control group ( P<0.05). No HBOT-related adverse reaction was found in the HBOT group. Conclusion:The treatment combined with HBOT can improve the curative effect in the children with VE, reduce the times of seizure onset, and protect brain. This may be related to the role of HBOT in inhibiting TLR2/NF-κB pathway and regulating the balance of Th17/Treg.
